Wall Street Analysts See Cardinal (CAH) as a Buy: Should You Invest?

Core Viewpoint - Brokerage recommendations, particularly for Cardinal Health (CAH), show a strong positive bias, with an average brokerage recommendation (ABR) of 1.25, indicating a consensus between Strong Buy and Buy [2][5]. Group 1: Brokerage Recommendations - Cardinal Health has an ABR of 1.25, based on recommendations from 16 brokerage firms, with 14 of those being Strong Buy, representing 87.5% of all recommendations [2]. - Despite the strong ABR suggesting a buy, relying solely on this information may not be advisable, as studies indicate that brokerage recommendations often fail to guide investors effectively [5][11]. - Analysts from brokerage firms tend to exhibit a positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" [6][11]. Group 2: Zacks Rank vs. ABR - The Zacks Rank, which classifies stocks from 1 (Strong Buy) to 5 (Strong Sell), is a more reliable indicator of near-term price performance compared to ABR, as it is based on earnings estimate revisions [8][12]. - The Zacks Rank is updated more frequently than ABR, reflecting timely changes in earnings estimates, which are crucial for predicting future stock prices [13]. - Cardinal Health currently holds a Zacks Rank 2 (Buy), supported by a 2.3% increase in the Zacks Consensus Estimate for the current year, now at $10.31 [14][15].